Clinical trials: Cytokine Release Syndrome
Critical Illness, Corona Virus Infection
Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19
The cytokine storms mediated by over production of proinflammatory cytokines have been observed in a large population of critically ill patients infected with COVID-19.
- Conditions
- Critical Illness, Corona Virus Infection, Cytokine Release Syndrome
- Trial name
- NCT04486521
- Testing
- Interleukin 6 (IL6) Antagonist, Interleukin 6 (IL6) Antagonist and corticosteroids, corticosteroid alone
- Where
- Saudi Arabia
- Volunteers
- 860 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Cytokine Release Syndrome
Jafron Haemoadsorption During Cardiopulmonary Bypass
Cardiopulmonary bypass (CPB) is often associated with degrees of complex inflammatory response mediated by various cytokines. This response can, in severe cases, lead to systemic hypotension and organ dysfunction.
- Trial name
- JAFRONCPB (NCT05349669)
- Testing
- Jafron use during CPB
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Anthea Hospital Bari
Hemophagocytic Lymphohistiocytoses, Cytokine Storm
Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is a rapidly fatal disease caused by immune-dysregulation characterized by hypercytokinemia, with about 30%-40% of patients suffering death in children.
- Trial name
- NCT05491304
- Testing
- Dexamethasone, Etoposide, Ruxolitinib
- Where
- China
- Volunteers
- 400 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Solid Tumor, Hematological Malignancy
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
The aim of this prospective study is to evaluate the feasibility and efficacy of metoprolol, a beta-1 adrenergic receptor blocker, in the treatment of cytokine release syndrome (CRS) caused by chimeric antigen receptor T (CAR T)…
- Trial name
- NCT04082910
- Testing
- Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Paediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-Cov-2
Paediatric Inflammatory Multisystem Syndrome During COVID-19 Pandemic
During the COVID-19 pandemic, a small minority of children have been presenting to acute paediatric services with a new syndrome, Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS-Cov-2 (PIMS-TS).
- Trial name
- NCT04761913
- Where
- 6 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Anglia Ruskin University
Dengue, Dengue With Warning Signs
Anakinra in Dengue With Hyperinflammation ( AnaDen )
This study aims to evaluate the effect of anakinra in dengue patients with hyperinflammation as compared to placebo Primary Objective: To evaluate the efficacy of Anakinra in moderate-severe dengue patients with…
- Conditions
- Dengue, Dengue With Warning Signs, Severe Dengue, Anakinra
- Trial name
- NCT05611710
- Testing
- Anakinra
- Where
- Vietnam
- Volunteers
- 160 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Diabetes Mellitus, Type 1
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
The aim of this Phase I/IIa study is to identify a safe and tolerable dosage regimen of intravenously administered otelixizumab.
- Trial name
- NCT02000817
- Testing
- Otelixizumab
- Where
- 6 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Sepsis, Cytokine Storm
Effect of Cytosorb on Blood Levels of Inflammatory Biomarkers of Sepsis.
Background: There is still an evident need for useful biomarkers and effective therapeutic approaches regarding the challenging management of sepsis.
- Trial name
- NCT04226430
- Testing
- Cytokine aphaeresis
- Volunteers
- 34 people
- Sponsor
- University of Gaziantep
Cytokine Release Syndrome
A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
"The purpose of this study is to assess the safety and efficacy of oral administration of itacitinib for the prevention of cytokine release syndrome (CRS) in male or female participants aged 12 years or older and who are planning…
- Trial name
- NCT04071366
- Testing
- Itacitinib, Immune effector cell therapy, Yescarta
- Where
- 10 sites in United States
- Volunteers
- 112 people
- Sponsor
- Incyte Corporation
Acute Lymphoblastic Leukemia, Immune System Diseases
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
The body has different ways of fighting infection and disease. No single way is effective at fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells.
- Conditions
- Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
- Trial name
- NCT03016377
- Testing
- iC9-CAR19 cells, Rimiducid, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Lymphoblastic Leukemia, CD19 Positive
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
This is a single center,randomized ,two-cohorts, open-label ,phase 1/2 study to evaluate the efficacy and safety of T cells expressing CD19 chimeric antigen receptors treatment for relapsed/refractory CD19+ acute lymphoblastic…
- Conditions
- Acute Lymphoblastic Leukemia, CD19 Positive, Relapse, Refractory
- Trial name
- NCT03275493
- Testing
- CD19 CAR-T cells, CD19 CAR-T cells with CRS suppression technology
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Immune and Microbial Reconstitution, Systemic Viral Infection
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
This protocol serves as a mechanism to collect, store, and distribute bodily fluid and tissue samples obtained from Hematopoietic Cell Transplant (HCT) or novel immunotherapy patients and their donors at the Masonic Cancer Center…
- Conditions
- Immune and Microbial Reconstitution, Systemic Viral Infection, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
- Trial name
- NCT03557749
- Testing
- Blood Sample, Stool Sample, Urine Sample
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Cytokine Release Syndrome, COVID19
Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
This protocol will evaluate the efficacy of Therapeutic Plasma Exchange (TPE) alone or in combination with ruxolitinib in COVID positive patients with PENN grade 2, 3, 4 cytokine release syndrome (CRS).
- Trial name
- NCT04374149
- Testing
- Therapeutic Plasma Exchange, Ruxolitinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Prisma Health-Upstate
B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy
Pre-emptive Anakinra for Cytokine Event Reduction
Objectives: The primary objective of this study will be to evaluate the impact of pre-emptive use of anakinra on the rate of severe cytokine release syndrome (CRS) following CD19-directed chimeric antigen receptor (CAR) T-cell…
- Conditions
- B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome
- Trial name
- PACER (NCT06703216)
- Testing
- Anakinra (Kineret®)
- Where
- United States
- Sponsor
- Kevin McNerney
Covid19
TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
Investigators conducted this study to see the effectiveness of Tocilizumab in COVID-19 participants who were in cytokine release syndrome and there was also a control group who received steroids(RECOVERY TRIAL wasn't published or…
- Trial name
- NCT04730323
- Testing
- Tocilizumab
- Where
- Pakistan
- Volunteers
- 93 people
- Sponsor
- FMH College of Medicine and Dentistry
Depressive Disorder, Fatigue Syndrome, Chronic
Glucocorticoid Effects on Cellular Cytokine Release
A variety of hormones and immune system processes are responsible for how the body responds to illness. This study concentrates on how the hormone cortisol effects the release of immune system factors called cytokines.
- Conditions
- Depressive Disorder, Fatigue Syndrome, Chronic, Fibromyalgia, Healthy
- Trial name
- NCT00001415
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Stem Cell Transplant Complications, Cytokine Release Syndrome
Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome
Phase II, randomized controlled, unblinded clinical trial. Will evaluate whether the administration of oral cyclosporine started on day 0 of transplantation is effective in reducing the incidence of cytokine release syndrome…
- Trial name
- NCT04781803
- Testing
- Cyclosporine
- Where
- Mexico
- Volunteers
- 32 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Lymphoblastic Leukemia, Acute, Childhood
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated cytokine release syndrome safety events in pediatric patients with CD19 expressing…
- Trial name
- NCT02906371
- Testing
- Tocilizumab, CART 19
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Pennsylvania
DHA as Antioxidant Anti-inflammatory Immunomodulation , Overcome Cytokine Storm
Observational Study of Infants Fed on DHA (Breast Source or Milk Formula Source ) and Its Effects on Covid-19 Infected Infants and Severity
Observational Study of Infants Fed on DHA (Breast Source or Milk Formula Source ) and Its Effect on COVID-19 Severity Amr kamel khalil Ahmed ( drmedahmed@gmail.com ) Director of tuberculosis program Ghubera, public health…
- Trial name
- NCT05071690
- Where
- 2 sites in Egypt, Saudi Arabia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Saudi Arabia